Abstract |
The need to treat diseases affecting the nicotinic AChR is great, but therapeutic options are few. Through careful correlation of structure-activity relationships of AnTX analogs, we may ultimately be led to the development of diagnostic and therapeutic drugs with specific nicotinic agonist or antagonist activities in the central nervous system that would be of major importance in the treatment of Alzheimer's disease.
|
Authors | K L Swanson, E X Albuquerque |
Journal | Maryland medical journal (Baltimore, Md. : 1985)
(Md Med J)
Vol. 41
Issue 7
Pg. 623-31
(Jul 1992)
ISSN: 0886-0572 [Print] United States |
PMID | 1640819
(Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S., Review)
|
Chemical References |
- Receptors, Nicotinic
- Toxoids
|
Topics |
- Animals
- Electrophysiology
- Humans
- Nervous System
(metabolism)
- Nervous System Physiological Phenomena
- Receptors, Nicotinic
(drug effects, metabolism, physiology)
- Toxoids
(pharmacology)
|